Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study


23 Nov 2019


Poster display session


Tumour Site

Colon and Rectal Cancer


Jasur Madyarov


Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421


J.M. Madyarov, A. Rasulov, Z. Mamedli, D. Kuzmichev

Author affiliations

  • Colorectal, N. N. Blokhin National Medical Research Center of Oncology, 117535 - Moscow/RU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 111P


In present time, neoadjuvant chemoradiotherapy for distal rectal cancer is part of clinical guidelines in Europe and the USA. According to the literature, there are no unified standards for upper rectal cancer.


The study included data from patients over 18 years old, with histologically proven adenocarcinoma with TNM stage T2-4aN0-2M0 and tumour location in the upper part of the rectum (10-15 sm). In the main group (A), preoperative chemoradiotherapy was performed: short-course radiotherapy (5x5 Gy), with capecitabine 2000 mg/m2 × 2 times for 14 days, followed by surgical treatment. In the control group (B) only surgical treatment was performed - partial or total mesorectumectomy.


From January 2004 to December 2014, 226 (99.6%) underwent surgical treatment. The incidence of postoperative complications byClavien-Dindo scale was:group A - 17 (16.5%) and group B - 11 (8.9%). Local recurrences in group A occurred in 1 patient (1.2%), in group B - in 3 (2.5%) patients (p = 0.413). Distant metastases in group A developed in 10 (10.2%) patients, in group B -15 (12.6%) patients (p = 0.581). Overall survival was in group A - 90.6%, recurrence-free - 89.6%; in group B - 82.8% and 81.9%, respectively (p = 0.46). Multivariate analysis showed that the affected regional lymph nodes were the main predictor of poor prognosis (p = 0.001, OR = 0.094, CI = 0.035-0.250) and significantly reduced the 5-year disease-free survival rate (p = 0.001, OR = 4.213, CI = 2.010-8.830).


The results of the study showed that neoadjuvant chemoradiotherapy in comparison with the surgical method does not have an advantage for patients with upper rectum cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Jasur Madyarov.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.